S-1 and CPT-11 plus ramucirumab (IRIS1Rmab) as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: A multicenter phase II study in Japan (N-DOCC-F-C-1701)

被引：0
|
作者：
Kobayashi, K. [1 ]
Morita, M. [1 ]
Ito, S. [1 ]
Inoue, Y. [1 ]
Yamaguchi, I. [1 ]
Kosaka, T. [1 ]
Kuba, S. [1 ]
Sakimura, C. [1 ]
Soyama, A. [1 ]
Adachi, T. [1 ]
Ohno, S. [1 ]
Kobayashi, S. [1 ]
Hara, T. [1 ]
Hidaka, M. [1 ]
Hayashida, N. [1 ]
Yamanouchi, K. [1 ]
Kanetaka, K. [1 ]
Takatsuki, M. [1 ]
Eguchi, S. [1 ]
机构：
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Surg, Nagasaki, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
192TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702)
    Yoshinari Mochizuki
    Norifumi Ohashi
    Hiroshi Kojima
    Kiyoshi Ishigure
    Takashi Kinoshita
    Takehiko Eguchi
    Shinichi Fujitake
    Seiji Ito
    Michitaka Fujiwara
    Yasuhiro Kodera
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 629 - 635
  • [22] Phase II study of irinotecan and bevacizumab plus alternate day S-1 as second-line treatment in patients with metastatic colorectal cancer.
    Tanaka, Chihiro
    Matsuda, Chu
    Kondo, Ken
    Tokunaga, Yukihiko
    Takahashi, Takao
    Kosugi, Chihiro
    Takemoto, Hiroyoshi
    Iwamoto, Shigeyoshi
    Oba, Koji
    Sakamoto, Junichi
    Mishima, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [23] A multicenter phase II study of S-1 combined with irinotecan (CPT-11) for patients with advanced/recurrent breast cancer
    Toh, U.
    Iwakuma, N.
    Otsuka, H.
    Takenaka, M.
    Ogo, E.
    Fujii, T.
    Tanaka, M.
    Shirouzu, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Irinotecan (CPT-11) plus raltitrexed as second line chemotherapy (CT) in metastatic colorectal cancer: A phase II study. Preliminary results.
    Caroti, C
    Aschele, C
    Mammoliti, S
    D'Amico, M
    Torrisi, R
    Gallo, L
    ANNALS OF ONCOLOGY, 2000, 11 : 65 - 65
  • [25] Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer
    Yoshimatsu, Kazuhiko
    Yokomizo, Hajime
    Fujimoto, Takashi
    Umehara, Arihiro
    Otani, Taisuke
    Matsumoto, Atsuo
    Osawa, Gakuji
    Ogawa, Kenji
    ANTICANCER RESEARCH, 2007, 27 (3B) : 1657 - 1661
  • [26] Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701
    Kawase, Tomono
    Imamura, Hiroshi
    Goto, Masahiro
    Kimura, Yutaka
    Ueda, Shugo
    Matsuyama, Jin
    Nishikawa, Kazuhiro
    Sugimoto, Naotoshi
    Fujita, Junya
    Tamura, Takao
    Fukushima, Norimasa
    Kawakami, Hisato
    Sakai, Daisuke
    Kurokawa, Yukinori
    Shimokawa, Toshio
    Satoh, Taroh
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (10) : 1871 - 1880
  • [27] Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701
    Tomono Kawase
    Hiroshi Imamura
    Masahiro Goto
    Yutaka Kimura
    Shugo Ueda
    Jin Matsuyama
    Kazuhiro Nishikawa
    Naotoshi Sugimoto
    Junya Fujita
    Takao Tamura
    Norimasa Fukushima
    Hisato Kawakami
    Daisuke Sakai
    Yukinori Kurokawa
    Toshio Shimokawa
    Taroh Satoh
    International Journal of Clinical Oncology, 2021, 26 : 1871 - 1880
  • [28] A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study
    Chu Matsuda
    Michitaka Honda
    Chihiro Tanaka
    Ken Kondo
    Takao Takahashi
    Chihiro Kosugi
    Yukihiko Tokunaga
    Hiroyoshi Takemoto
    Ho Min Kim
    Junichi Sakamoto
    Koji Oba
    Hideyuki Mishima
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 1035 - 1041
  • [29] A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study
    Matsuda, Chu
    Honda, Michitaka
    Tanaka, Chihiro
    Kondo, Ken
    Takahashi, Takao
    Kosugi, Chihiro
    Tokunaga, Yukihiko
    Takemoto, Hiroyoshi
    Kim, Ho Min
    Sakamoto, Junichi
    Oba, Koji
    Mishima, Hideyuki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 1035 - 1041
  • [30] Phase II trial of a combination chemotherapy of CPT-11 and S-1 in patients with advanced/recurrent colorectal cancer (OGSG-0405)
    Tomita, N.
    Okamura, S.
    Nakata, K.
    Murata, K.
    Tokunaga, Y.
    Umeki, M.
    Takiuchi, H.
    Furukawa, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345